Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 0.54 |
| ▸ | CA1 | P00915 | 12/20 | 0.54 |
| ▸ | CA12 | O43570 | 6/20 | 0.54 |
| ▸ | CA9 | Q16790 | 6/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30958265 | 0.87 | CA2 (0.54) | CA2CA1CA12CA9IDO1 | |
| SCHEMBL1926110 | 0.87 | CA1 (0.52) | CA2CA1CA12CA9GAA | |
| SCHEMBL22015794 | 0.87 | CA1 (0.52) | CA2CA1CA12CA9GAA | |
| SCHEMBL22015786 | 0.86 | CA1 (0.51) | CA2CA1CA12CA9GAA | |
| SCHEMBL3184725 | 0.86 | KMT2A (0.52) | CA2CA1CA12CA9TDP1 | |
| SCHEMBL1542090 | 0.86 | L3MBTL1 (0.57) | CA2CA1CA12CA9MALT1 | |
| SCHEMBL3711894 | 0.85 | CA1 (0.50) | CA2CA1CA12CA9GAA | |
| SCHEMBL447708 | 0.84 | CA1 (0.49) | CA2CA1CA12CA9 | |
| SCHEMBL21963915 | 0.83 | CA1 (0.48) | CA2CA1CA12CA9GAA | |
| SCHEMBL3228310 | 0.83 | CA2 (0.49) | CA2CA1CA12CA9MALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017516-A1 | LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-01-20 | — | — | US | disclosed |
| WO-2020099886-A1 | LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017516-A1 | LOX INHIBITORS | LOXL1, LOX, LOXL2 | CA2 2865/4885CA1 4120/4885CA12 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.